https://www.selleckchem.com/pr....oducts/glumetinib.ht
Yan, Zhang, Zhou, Wang and Dai.In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating treatment moved from the delay of progression to the induction of the deepest possible response. As a result of these advances, a great scientific effort has been made to redefine response monitoring, resulting in the development and validation of high-sens
Gefällt mir
Kommentar
Teilen
